Sucroferric oxyhydroxide is a new iron-based phosphate binder in the family of iron-based phosphate binders. It is a combination of iron hydroxide and sucrose, which is designed to control phosphorus levels in the blood of patients with chronic kidney disease (CKD). It works by binding to dietary phosphorus in the intestine, preventing its absorption and reducing the amount of phosphorus that enters the bloodstream. Sucroferric oxyhydroxide has been approved for use in the United States, Europe, and other countries. Clinical studies have demonstrated that sucroferric oxyhydroxide is effective at reducing serum phosphorus levels in CKD patients. In addition, it has been shown to be safe and well tolerated, with a very low risk of gastrointestinal side effects.
Sucroferric oxyhydroxide is a medication sold under the brand name Velphoro. It's a non-calcium, iron-based phosphate binder used to control serum phosphorus levels in adults with chronic kidney disease (CKD) on hemodialysis (HD) or peritoneal dialysis (PD). It comes in the form of chewable tablets.
Sucroferric oxyhydroxide works by binding to phosphate in the gastrointestinal tract, preventing it from being absorbed into the bloodstream. This helps to lower blood phosphorus levels in people with chronic kidney disease who are unable to properly eliminate phosphorus from their bodies.
Here's a summary of Sucroferric oxyhydroxide:
- What it is: A medication used to control phosphorus levels in adults with chronic kidney disease.
- Brand name: Velphoro
- How it works: Binds to phosphate in the digestive tract, preventing its absorption into the bloodstream.
- Dosage: Taken as chewable tablets, usually three times a day with meals.
- Side effects: The most common side effects include diarrhea and discolored feces.